IONIS PHARMACEUTICALS INC (IONS) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds adding versus the previous quarter. Insiders were net buyers over the last 90 days ($148.2K bought vs $61.4K sold). Latest close $27.39 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.
Tweedy Browne · Deep Track Capital · Deerfield Management — 5 tracked funds hold IONS. See all holders.
Insiders bought on the open market (1 purchase, $148.2K) vs 2 sales ($61.4K). Latest buy: Nov 10, 2026. Insider trading
AVALYN PHARMA INC (AVLN) · NURIX THERAPEUTICS INC (NRIX) · Celcuity Inc. (CELC) · COGENT BIOSCIENCES INC (COGT) · DYNE THERAPEUTICS INC (DYN) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Tweedy Browne | 13.70% | 2,280,311 | ADDED (+0.2%) Q3 filed Nov 4 |
| Deep Track Capital | 2.54% | 2,200,000 | ADDED (+12.8%) Q3 filed Nov 16 |
| Deerfield Management | 1.64% | 1,979,669 | HELD Q3 filed Nov 16 |
| Baker Bros. Advisors | 0.81% | 2,047,727 | HELD Q3 filed Nov 16 |
| Perceptive Advisors | 0.67% | 566,000 | ADDED (+12.3%) Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -66.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 518 of 8,857 filers |
| Long-only filers among them | 511 |
| Change vs 2026 Q1 | +31 net · 485 entered · 454 exited |
| Shares reported, all filers | 179,686,810 |
| Reported value, all filers | $14.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $943.7M |
| Net income · FY2025 | $-381.4M |
| Total assets · FY2025 | $3.5B |
| Shares outstanding | 166,184,322 |
| Market cap (at latest close) | $4.6B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 23, 2026.
| Shares short · Oct 15, 2026 | 20,653,026 |
| Share of shares outstanding | 12.43% |
| Days to cover | 7.65 |
Shares short at recent settlements — Jul 31, 2026: 21.5M · Aug 14, 2026: 20.9M · Aug 31, 2026: 20.9M · Sep 15, 2026: 20.9M · Sep 30, 2026: 22.5M · Oct 15, 2026: 20.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 23, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 200 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 23, 2026.
1 insider bought on the open market in the last 90 days (1 purchase, $148.2K), against 2 sales by 2 insiders ($61.4K). Latest buy: Nov 10, 2026.
Source: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| Hayden Michael R · 5,000 shares on Nov 10, 2026 · filed Nov 13, 2026 | $29.64 | -3.8% (close Nov 16, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Nov 16, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Hayden Michael R | Buy | 5,000 | $29.64 | $148.2K | SEC filing | |
| Oct 16, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell | 1,357 | $43.54 | $59.1K | SEC filing |
| Oct 16, 2026 | Swayze Eric | EVP Research | Sell | 53 | $43.54 | $2.3K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Diaz Allene M. | Director | 10,111 | $863.6K | Jul 7, 2026 | SEC filing |
| Jul 7, 2026 | Kordasiewicz Holly B. | Officer | 1,287 | $108.5K | Jul 7, 2026 | SEC filing |
| Jul 7, 2026 | BENNETT C FRANK | Officer | 67,386 | $5.7M | Jul 7, 2026 | SEC filing |
| Jul 1, 2026 | KLEIN JOSEPH III | Director | 11,518 | $910.4K | Jul 1, 2026 | SEC filing |
| Jun 26, 2026 | Baroldi Mariana | Member of immediate family of any of the foregoing | 5,635 | $451.7K | Jun 26, 2026 | SEC filing |
| Jun 26, 2026 | O'NEIL PATRICK R. | Officer | 3,069 | $245.5K | Jun 26, 2026 | SEC filing |
| Jun 26, 2026 | Schneider Eugene | Officer | 47,884 | $3.9M | Jun 26, 2026 | SEC filing |
| Jun 25, 2026 | Swayze Eric | Officer | 10,602 | $839.3K | Jun 25, 2026 | SEC filing |
| Jun 15, 2026 | BERTHELSEN SPENCER R | Director | 8,000 | $587.9K | Jun 15, 2026 | SEC filing |
| Jun 12, 2026 | Kordasiewicz Holly B. | Officer | 60,846 | $4.5M | Jun 12, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 15, 2026 | T. Rowe Price Investment Management, Inc. | SC 13G/A | 6,159,027 | 3.7% | Mar 31, 2026 | SEC filing |
| May 14, 2026 | Capital World Investors | SC 13G/A | 21,186,369 | 12.8% | Mar 31, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 8,344,732 | 5.0% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | T. Rowe Price Investment Management, Inc. | SC 13G/A | 9,108,019 | 5.6% | Dec 31, 2025 | SEC filing |
| Jan 7, 2026 | Capital World Investors | SC 13G/A | 17,961,299 | 11.1% | Dec 31, 2025 | SEC filing |
| Nov 14, 2025 | T. Rowe Price Investment Management, Inc. | SC 13G/A | 13,157,114 | 8.3% | Sep 30, 2025 | SEC filing |
| Aug 12, 2025 | Wellington Management Group LLP | SC 13G/A | 6,879,873 | 4.3% | Jun 30, 2025 | SEC filing |
| Apr 17, 2025 | BlackRock, Inc. | SC 13G/A | 9,066,517 | 5.7% | Mar 31, 2025 | SEC filing |
| Feb 13, 2025 | Capital World Investors | SC 13G | 11,465,413 | 7.3% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 18 Lobbying Disclosure Act filings named this company as client, 2024–2026; most common issues: Health Issues (18), Medicare/Medicaid (9), Taxation/Internal Revenue Code (8).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
This stock does not currently pass any tracked screen.
Also held by the tracked funds that hold IONS — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · NURIX THERAPEUTICS INC (NRIX) · Celcuity Inc. (CELC) · COGENT BIOSCIENCES INC (COGT) · DYNE THERAPEUTICS INC (DYN) · Immunovant, Inc. (IMVT) · Mirum Pharmaceuticals, Inc. (MIRM) · Praxis Precision Medicines, Inc. (PRAX).
| Filed | Items | Source |
|---|---|---|
| Nov 9, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 23, 2026 | 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 21, 2026 | 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on IONS
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.